US drugmaker Pfizer has reported a much better-than-expected quarterly profit, mainly helped by demand for its pneumonia vaccine and breast cancer drug, Ibrance.
The company also raised its full-year profit and revenue forecast for the second time in as many months.
Pfizer said its net income fell to $2.13 billion, or 34 cents per share, in the third quarter, from $2.67 billion, or 42 cents per share, a year earlier.
On an adjusted basis, the company earned 60 cents per share, above the analysts' average estimate of 51 cents per share, according to the Thomson Reuters I/B/E/S.
Revenue fell 2% to $12.09 billion, but was above the analysts' estimate of $11.56 billion.
The largest US drugmaker said revenue from its global vaccines business rose 43% to $1.63 billion.
The unit, which includes the Prevnar 13 pneumonia vaccine, contributed about 13.5% to the company's total revenue.
Pfizer said it was raising its 2015 revenue range by $1 billion to $47.5 billion-$48.5 billion.
